268 related articles for article (PubMed ID: 34091006)
1. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.
Hakeam HA; Alsahli H; Albabtain L; Alassaf S; Al Duhailib Z; Althawadi S
Int J Infect Dis; 2021 Aug; 109():1-7. PubMed ID: 34091006
[TBL] [Abstract][Full Text] [Related]
2. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.
Zhen S; Lin Q; Chen Z; Shen Y; Chen X; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Jiang E; Han M; Wang J; Feng S
J Infect Chemother; 2024 Jul; 30(7):608-615. PubMed ID: 38215820
[TBL] [Abstract][Full Text] [Related]
4. Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.
Shields RK; Nguyen MH; Hao B; Kline EG; Clancy CJ
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891598
[TBL] [Abstract][Full Text] [Related]
5. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
[TBL] [Abstract][Full Text] [Related]
9. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
Shields RK; Nguyen MH; Chen L; Press EG; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507064
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.
Castón JJ; Lacort-Peralta I; Martín-Dávila P; Loeches B; Tabares S; Temkin L; Torre-Cisneros J; Paño-Pardo JR
Int J Infect Dis; 2017 Jun; 59():118-123. PubMed ID: 28392315
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
13. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
Sousa A; Pérez-Rodríguez MT; Soto A; Rodríguez L; Pérez-Landeiro A; Martínez-Lamas L; Nodar A; Crespo M
J Antimicrob Chemother; 2018 Nov; 73(11):3170-3175. PubMed ID: 30099490
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
[TBL] [Abstract][Full Text] [Related]
16. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study.
Rathish B; Wilson A; Warrier A; Prakash S; Babu R; Joy S
Cureus; 2021 Feb; 13(2):e13081. PubMed ID: 33680621
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam.
Jorgensen SCJ; Trinh TD; Zasowski EJ; Lagnf AM; Bhatia S; Melvin SM; Simon SP; Rosenberg JR; Steed ME; Estrada SJ; Morrisette T; Davis SL; Rybak MJ
Infect Dis Ther; 2020 Jun; 9(2):291-304. PubMed ID: 32088843
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales.
Mataraci Kara E; Yilmaz M; Istanbullu Tosun A; Özbek Çelik B
J Chemother; 2020 Jul; 32(4):171-178. PubMed ID: 32375606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
